论文部分内容阅读
目的总结抗甲状腺药物治疗(ATD)致粒细胞减少的临床特点及治疗措施。方法回顾本院收治的16例ATD致粒细胞减少患者的临床资料。结果 11例在1~3周内粒细胞恢复正常,5例迁延到3个月内。结论粒细胞减少多发生在用药初期,易至粒细胞缺乏,是ATD最严重的不良反应,应早期监测血常规,早期防治粒细胞减少及粒细胞缺乏症。
Objective To summarize the clinical features and treatment of antithyroid drug therapy (ATD) induced neutropenia. Methods The clinical data of 16 patients with ATD neutropenia admitted to our hospital were retrospectively reviewed. Results In 11 cases, granulocytes returned to normal within 1 ~ 3 weeks and 5 cases were delayed to within 3 months. Conclusions Most of the neutropenia occurs in the early stage of medication, and is easy to have agranulocytosis. It is the most serious adverse reaction of ATD. Early monitoring of blood routine, early prevention and treatment of neutropenia and agranulocytosis should be performed.